Skip to main content
main-content

Type 2 diabetes

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

SGLT2 inhibition ‘could overcome diuretic resistance’

Man handing container with urine sample to a doctor

A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

Flatline alert_heart monitor

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

Pills and water (symbolic image with model)

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

medwireNews top story

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

Kidneys

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

medwireNews top story

‘Nearly identical’ metabolic benefits with surgery vs diet in people with type 2 diabetes

Bariatric surgery

Among people with obesity and type 2 diabetes, substantial weight loss is associated with similar metabolic benefits irrespective of whether it is achieved through gastric bypass surgery or diet, suggests research published in The New England Journal of Medicine.

medwireNews top story

Type 1, type 2 diabetes linked to elevated COVID-19 mortality risk

Doctor checking on Covid-19 infected patient connected to a ventilator

Both type 1 and type 2 diabetes are independently associated with an increased risk for death among hospitalized patients with COVID-19, and a number of factors including poor glycemic control and BMI may predict mortality risk, suggest findings from two studies published in The Lancet Diabetes & Endocrinology.

medwireNews top story

Ethnic-specific diabetes screening BMI cutoffs proposed

African American male patient having weight checked by doctor

Researchers studying the MESA cohort have proposed BMI cutoffs at which people from ethnic minorities should be screened for type 2 diabetes, all of which are lower than their proposed cutoff for White people.

medwireNews top story

Severe hypoglycemia ‘marker rather than cause’ for longer-term type 2 diabetes mortality risk

emergency_department

Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.

medwireNews top story

Nonvascular comorbidities highlighted in type 2 diabetes

Doctor patient consultation

A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.

medwireNews top story

Key danger times identified for US Diabetes Prevention Program dropout

Fallen stick figure in a race reaching for help

Focusing efforts on convincing people to return after the first session of the US National Diabetes Prevention Program lifestyle change program, and after the transition to less frequent sessions, may help to optimize program retention, say researchers.

medwireNews top story

Neighborhood walkability may reduce ethnic disparities in diabetes risk

Women with headscarfs sitting in Barcelona city

The increased risk for prediabetes among ethnic minorities compared with White people is less pronounced in neighborhoods with high walkability, shows a Canadian study.

ADA 2020

First weekly insulin shows equivalence with glargine in type 2 diabetes

Weekly calendar

A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.

ADA 2020

Icosapent ethyl lowers cardiovascular risk in people with diabetes

Heart and stethoscope

Icosapent ethyl reduces the risk for first and total cardiovascular events in statin-treated patients with diabetes, suggests a subgroup analysis of the REDUCE-IT trial.

medwireNews top story

‘Compelling evidence’ of greater diabetes treatment inertia for ethnic minorities

Mixed diabetes medications

Doctors are faster to initiate pharmacologic type 2 diabetes treatment in people from ethnic minorities than in White people but are then slower to intensify their treatment when needed, show data from the UK.

medwireNews top story

Cardiometabolic burden varies by age, sex, ethnicity at type 2 diabetes diagnosis

People in profile different age and nationalities

A study shows marked variations in cardiovascular risk burden according to age, sex, and ethnicity at the point of type 2 diabetes diagnosis, with implications for both diabetes prevention and cardiovascular risk management.

The continuing evolution of GLP-1RAs – webcast available now!

The continuing evolution of GLP-1RAs

Don’t miss out on this expert-led webcast on the continuing evolution of glucagon-like peptide-1 receptor agonists, chaired by Professor John Wilding.

medwireNews top story

Genetic markers of type 2 diabetes risk in East Asian people uncovered

DNA_multicoloured

A major genetic analysis sheds light on the similarities and differences in type 2 diabetes pathogenesis between people of East Asian and European origin.

Expert opinion editorial

Oral semaglutide: A technical triumph, with caveats

Balancing pros and cons

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide [read more].

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

medwireNews top story

Prediabetes marks increased vascular risk

Cartoon of overweight man walking on a 'cardiovascular tightrope'

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

Podcast

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?

Neil Skolnik

US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26) [Listen now]

Get more on: Type 2 diabetes medications | GLP-1 receptor agonists

07-29-2020 | Type 2 diabetes | Podcast | Article

The DiRECT approach to weight loss: Efficacious and pragmatic

DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).

06-24-2020 | ADA 2020 | Conference coverage | Article

ADA 2020 goes virtual! Editorial Board conference highlights

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

Diagnosis and management of prediabetes: a consensus of GCC countries

Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.

This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. 

Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC

Access the interactive roadmap

Downloadable slides

10-31-2018 | Slideset | Collection

FreeStyle Libre collection

These slide sets summarize the results of clinical studies and randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.

Funded by an educational grant from Abbott Diabetes Care

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Image Credits